Circulating tumor DNA (ctDNA) has already shown clinically relevant results in early-stage colon cancer patient management. Its prognostic value is by far
NCCN Clinical Practice Guidelines in Oncology: colon cancer. The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, ... P Engstrom,J. P. Arnoletti,A. Benson,... - 《J Natl Compr Canc ...
In patients with advanced or metastatic colon cancer, the NCCN guidelines indicate that neoadjuvant chemotherapy may be considered.[15] The potential value of adjuvant chemotherapy for patients with stage II colon cancer remains a matter of debate.[1,6] Common chemotherapy regimens include, but are...
Molecular analysis, including oncogenic alterations (KRAS/NRAS/BRAF), mismatch repair (MMR) status, and microsatellite instability status, is recommended for mCRC according to the National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2022 for colon cancer[6]. It is estimated that approximate...
Colorectal cancer is a heterogeneous disease, with at least three well-known major, molecularly defined groups: the chromosomal instable, the microsatellite instable and the CpG island methylator phenotype. Although these groups differ in pathology, outcome and response to therapy, this classification is...
In the past decades the incidence of colorectal cancer (CRC) in people under the age of 50 years has increased, which is referred to as early-onset CRC or young-onset CRC (YO-CRC). YO-CRC is expected to account for 11% of colon cancers and 23% of rectal
Advanced Colorectal CancerColon CancerCancer NetworksAnti-Angiogenesis DrugsThis article talks about updated guidelines for the treatment of advanced colorectal cancer. The guidelines identifies three key agents that...
66, 67 Comprehensive guidelines for CRC detection, prevention, and risk reduction are provided by organizations such as the American Cancer Society (ACS), American College of Physicians (ACP), National Comprehensive Cancer Network (NCCN), and the United States Preventive Services Task Force (UPSTF)...
Colorectal cancer liver metastasis (CRLM) is one of the leading causes of death among patients with colorectal cancer (CRC). Although immunotherapy has demonstrated encouraging outcomes in CRC, its benefits are minimal in CRLM. The complex immune landsca
Benson AB, Venook AP, Al-Hawary MM et al (2022) Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(10):1139–1167. https://doi.org/10.6004/jnccn.2022.0051 Article CAS PubMed Google Scholar André T, Boni C, Mounedji-Boudiaf L, ...